Скачать или смотреть Vaxil Bio Discusses Approach, Progress and Next Steps for Their COVID-19 Vaccine in Development

SNNLive spoke with David Goren, Chairman and CEO of Vaxil Bio Ltd. (TSX-V: VXL), via Zoom to discuss (Click the time stamp to jump to each answer, or watch it all):

1:47 Company's approach and progress for COVID-19 Vaccine
4:20 Next steps to get the vaccine across the finish line
7:58 Regulatory process
9:20 History of the company prior to COVID-19 Vaccine Focus
12:53 David Goren's background prior to joining Vaxil Bio
14:31 Goals and vision for the rest of 2020

For more information about Vaxil Bio Ltd., please visit: https://vaxil-bio.com/

The interview may contain forward looking statements about Vaxil Bio Ltd. See Vaxil Bio Ltd.'s periodic filings with SEDAR for more complete information.

About Vaxil Bio Ltd.

Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin™ successfully completed a Phase 1/2 clinical trial in multiple myeloma and received orphan drug status from the FDA and EMA. The company continues to develop ImMucintm and is also developing a tuberculosis vaccine / treatment that has demonstrated promising preliminary results with further preclinical evaluation underway at a top US academic and research institution. Additional indications and mAb candidates are under evaluation as immuno-oncology and infectious disease treatments alone and in combination with other treatments.

Vaxil exploits the unique properties of signal peptide domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens. These signal peptide domains are identified by VaxHit™, Vaxil's proprietary bioinformatic approach. These SPs induce a robust T- and B-cell response across wide and varied HLA subtypes, while acting as true, universal neoantigens. The peptide platform targets these cells by "educating" or specifically activating the immune system to recognize and attack the affected cells. In addition, Vaxil's mAb platform directly recognizes the target protein expressed on malignant cells and recruits other elements of the immune system to lyse those cells.

Subscribe NOW to SNN Network: http://bit.ly/1Q5Yfym

New videos are added almost every day to the SNN Network channel sharing fascinating stories and companies from the MicroCap stock market.

Get more SNN Network:
Website: http://stocknewsnow.com/
Follow Stock News Now:   / stocknewsnow  
Like Stock News Now:   / snninc  
Follow Stock News Now on LinkedIn:   / stoc.  .
Follow Stock News Now on StockTwits: http://stocktwits.com/StockNewsNow

SNN.Network is the Official YouTube Channel for the Small-, Micro- and Nano-cap markets by providing news, insights, education tools and expert commentary. Subscribe now to be notified when new CEO video interviews, WALL STREET VIEWS with investing experts and new episodes of the Planet MicroCap Podcast are LIVE!